Theratechnologies Inc T.TH

RE:RE:RE:One horrible way

[qwerty22]

The other example I showed today. Hopefully this link works.

https://www.dovepress.com/emerging-treatment-options-for-the-treatment-of-metastatic-urothelial--peer-reviewed-article-CMAR

They started pre-screening for their target (NECTIN) then dropped this screen when they discovered their target in 80% of the patient population. I'm sure Theratech will be screening for Sortilin at some point in the program to understand Sort1 expression levels impact on efficacy.

jfm1330 wrote: Overexpression of Sortilin receptors needs to be real, otherwise, obviously, the whole thing is worthless. That is why I was suggesting the isotopic approach for tomor  imaging a while ago.

In neuroendocrine cancers, now, they can assess somatostatin receptors expression by simply injecting a peptide with affinity to somatostatin receptors. This peptide has the isotope Gallium 68 linked to it. The small radiation from the isotope allows to quantify somatostatin receptors expression on the tumor by PET/CTScan. If the result shows overexpression of the somatostatin receptors on the tumors, then a treatment is made by injecting the same peptide (Dotatate) but this time linked to Lutetium 177. An isotope emitting stronger radiations. Strong enough to break DNA structure that will lead to cell death. Dotatate-Lu177 is the drug called Lutathera.

To me it is clear that before starting a phase I, Thera needs to be sure that Sortilin receptors are really overexpressed in the tumor the want to treat. I think the other method is through biopsy and some histological technique.

https://netrf.org/2018/11/13/gallium-68-scan-for-neuroendocrine-tumors/

 

Wino115 wrote: Always worth reminding ourselves of this.  Perhaps you science folks can understand the complexities referenced more.  But seems that the expression of FRa was a heck of a lot lower than the 80% some other study had showed them.

I still like the fact that the drug working on the tumor in the SORT1+ approach is an old drug, known to work.  The risk is two fold --one, like this paper where you find there isn't as much expression of the target as you thought, or it's not so tumor specific.  That other paper someone else put up here on Sortilin was powerful in backing up what the Montreal guys found though.  Second, will your drug attach and get in to that tumor cell effectively in humans.  Those seem to me to be the biggest risks.  I don't think there's as much risk in the next part of that chain, which is, if you targeted the tumor cell successfully and your "receiver" allowed you to enter it, did the drug you bring in work on the tumor cell.  I think given the history of Taxol and Rubicin we know that answer to that question is posiitve. 

qwerty22 wrote: the cancer study could go wrong (having seen the very many positive examples). Worth remembering the reality of what early phase means.

https://pubmed.ncbi.nlm.nih.gov/32984932/